To investigate whether dialysateconcentrations of substances that are locally produced within the peritoneal cavity can be used to study the effects of inflammation on peritoneal tissue.
Design
We followed the appearance rates (AR) of concentrations of cancer antigen (CA) 125, phospholipids (PHL), hyaluronan (HA), and the procollagen peptides PICP (procollagen 1 C-terminal) and PIIINP (procollagen 3 N-terminal) in dialysate during peritonitis (8 consecutive days) and after recovery. Data were compared with the stable situation.
Setting
CAPD (continuous ambulatory peritoneal dialysis) unit in the Academic Medical Center in Amsterdam.
Patients
Twelve CAPD patients with a total of 16 episodes of peritonitis and 10 clinically stable CAPD patients were studied.
Results
All substances showed temporal increments in dialysate during peritonitis compared to control. No difference was found between the control day of peritonitis and the stable patients. Maximum AR were reached in the acute phase of peritonitis for CA 125, PHL, and HA and on day 4 for both PICP and P111NP. A second increment in CA125 occurred on days 4 to 6. These findings indicate acute damage to the mesothelium (CA 125) and other cells (PHL) by the infection. HA may reflect stromal changes. Subsequently, peritoneal healing (PICP, PIIINP) and remesothelialization (second peak CA125) are likely to occur.
Conclusions
Dialysate concentrations of these substances can be used as markers for the effects of peritonitis on the peritoneum of CAPD patients in vivo. The similarity between the marker concentrations in the effluent after recovery from peritonitis and those in stable CAPD patients implies that complete peritoneal healing is likely to occur after uncomplicated peritonitis.
DobbieJ.W., ZakiM., WilsonL.Ultrastructural studies on the peritoneum with special reference to chronic ambulatory peritoneal dialysis.Scott Med J1981; 26: 213–23.
2.
DobbieJ.W., LloydJ.K., GallC.A.Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin, 1990; 6: 3–12.
3.
DobbieJ.W.New concepts in molecular biology and ultrastructural pathology of the peritoneum: their significance for peritoneal dialysis.Am J Kidney Dis1990; 15: 97–109.
4.
DobbieJ.W.Morpho-functional correlations in human mesothelium. In: La GrecaG., RoncoC., FerianiM., ChiaramonteS., ConzP., eds. Peritoneal dialysis.Milano: Wichtig Editore, 1991: 33–43.
5.
SlaterN.D., CopeG.H., RafteryA.T.Mesothelial hyperplasia in response to peritoneal dialysis fluid: a morphometric study in the rat.Nephron1991; 58: 466–71.
Di PaoloN., SacchiG., De MiaM.Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis.Nephron1986; 44: 204–11.
8.
GotloibL., ShostackA., Bar- ShellaP., CohenR.Continuous mesothelial injury and regeneration during long term peritoneal dialysis.Perit Dial Int1987; 7: 148–55.
9.
KoomenG.C.M., BetjesM.G.H., ZemelD., KredietR.T., HoekF.J.Dialysate cancer antigen (CA) 125 is a reflection of the peritoneal mesothelial mass in CAPD patients.Perit Dial Int1994; 14: 132–6.
10.
LipkinG.W., ForbesM.A., CooperE.H., TurneyJ.H.Hyaluronic acid metabolism and its clinical significance in patients treated by continuous ambulatory peritoneal dialysis.Nephrol Dial Transplant1993; 8: 357–60.
11.
JoffeP., JensenL.T.Type I and III procollagens in CAPD: markers of peritoneal fibrosis. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G., eds. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin, 1991; 7: 158–60.
12.
KabawatS.E., BastR.C., WelhW.R., KnappR.C., ColvinR.B.Immunopathologic characterisation of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types.Am J Clin Pathol1983; 79: 98–104.
13.
VisserC.E., Brouwer-SteenbergenJ.J.E., BetjesM.G.H., KoomenG.C.M., BeelenR.H.J., KredietR.T.Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients.Nephrol Dial Transplant1995; 10: 64–9.
14.
ZeillemakerA.M., VerbrughH.A., Hoynck van PapendrechtAAGM, LeguitP.CA 125 secretion by mesothelial cells.J Clin Pathol1994; 47: 263–5.
15.
GrahameG.R., TorchiaM.G., DankewichK.A., FergusonI.A.Surface-active material in peritoneal effluent of CAPD patients.Perit Dial Bull1985; 5: 109–11.
16.
Di PaoloN.The peritoneal mesothelium: an excretory organ.Perit Dial Int1989; 9: 151–4.
17.
DobbieJ.W., LloydJ.K.Mesothelium secretes lamellar bodies in a similar manner to type II pneumocyte secretion of surfactant.Perit Dial Int1989; 9: 215–19.
18.
HällgrenR., Engström-LaurentA, NisbethU.Circulating hyaluronate. A potential marker of altered metabolism of the connective tissue in uremia.Nephron1987; 46: 150–4.
19.
LaurentT.C.Structure of hyaluronic acid. In: BalzasE.A., ed. Chemistry and molecular biology in the intercellular matrix.London: Academic, 1970; 2: 703–32.
20.
KingS.R., HickersonW.L., ProctorK.C.Beneficial actions of exogenous hyaluronic acid on wound healing.Surgery1991; 109: 76–84.
21.
FesslerJ.H., FesslerL.I.Biosynthesis of procollagen.Ann Rev Biochem1978; 47: 129–62.
22.
RohdeH., VargasL., HahnE., KalbfleischH., BrugueraM., TimplR.Radioimmumoassay for type III procollagen peptide and its application to human liver disease.Eur J Clin Invest1979; 9: 451–9.
23.
ZemelD., KoomenG.C.M., HartA.A.M., ten BergeR.J.M., StruijkD.G., KredietR.T.The relationship of TNFα, interleukin-6 and prostaglandins to peritoneal permeability for macromolecules during the follow-up of CAPD related peritonitis.J Lab Clin Med1993; 122: 686–96.
24.
VasS.I.Microbiologic aspects of chronic ambulatory peritoneal dialysis.Kidney Int1983; 23: 83–92.
25.
BoeschotenE.W., RietraPJGM, KredietR.T., VisserM.J., AriszL.CAPD peritonitis: a prospective randomized trial of oral versus intraperitoneal treatment with cephradine.J Antimicrob Chemother1985; 16: 789–97.
26.
ZemelD., KredietR.T., KoomenG.C.M., StruijkD.G., AriszL.Day-to-day variability of protein transport used as a method for analyzing peritoneal permeability in CAPD.Perit Dial Int1991; 11: 217–33.
27.
VergerC., LugerA., MooreH.L., NolphK.D.Acutechanges in peritoneal morphology and transport properties in infectious peritonitis and mechanical injury.Kidney Int1983; 23: 823–31.
28.
ZieglerC., TorchiaM., GrahameG.R., FergusonI.A.Peritoneal surface-active material in continuous ambulatory peritoneal dialysis (CAPD) patients.Perit Dial Int1989; 9: 47–9.
29.
BeavisJ., HarwoodJ.L., ColesG.A., WilliamsJ.D.Intraperitoneal phosphatidylcholine levels in patients on continuous ambulatory peritoneal dialysis do not correlate with adequacy of ultrafiltration.J Am Soc Nephrol1993; 3: 1954–60.
30.
LaurentT.C., FraserJ.R.E.The properties and turnover of hyaluronan. In: EveredD., WhelanJ., eds. Functions of proteoglycans. Ciba Foundation Symposium.Chich ester: Wiley, 1986; 24: 9–29.
31.
DaviesM., StylianouE., YoungS., ThomasG.J., ColesG.A., WilliamsJ.D.Proteoglycans of CAPD-dialysate fluid and mesothelium.Contrib Nephrol1990; 85: 134–41.
ShahinM., SchuppanD., WaldherrR.Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease.Hepatology1992; 15: 637–44.
RennardS.I., JaurandM.C., BignonJ.Role of pleural mesothelial cells in the production of the submesothelial connective tissue matrix of lung.Am Rev Respir Dis1984; 130: 267–74.
36.
DavilaR.M., CrouchE.C.Role of mesothelial and submesothelial stromal cells in matrix remodeling following pleural injury.Am J Pathol1993; 142: 547–55.
37.
Degl'lnnocentiM.L., AltieriP., GhiggeriG.M., PerfumoF., GusmanoR.Characterization of extracellular matrix produced by peritoneal mesothelial cells “in vitro.”Nephrol Dial Transplant1994; 9: 1019.
